Weight loss in the GCC is no longer a narrow conversation around gyms, diets or appearance. A broader boom is emerging as three forces come together: a large population-level burden of obesity and diabetes, the expansion of weight management into managed consumer-health journeys, and the entry of medical weight-loss solutions such as GLP-1 drugs. This is shifting weight management from a lifestyle-led category into a broader consumer-health and metabolic-care market.
The opportunity is significant, but the category is also becoming more complex. As consumers move from self-directed diets and fitness programs toward nutrition products, digital tools, coaching, clinics and prescription-led solutions, the key question is whether the market can deliver safe, supervised and sustainable outcomes -not just faster weight reduction.
A large metabolic-health burden is creating the demand base
The starting point for the GCC’s weight-loss boom is the scale of underlying health need. GCC countries have among the highest overweight and obesity levels globally, with WHO EMRO noting that adult obesity prevalence in Kuwait, Qatar, Saudi Arabia and the UAE is more than double the global average. In Saudi Arabia, official 2024 data shows that 45.1% of adults aged 15+ are overweight and 23.1% are obese. In the UAE, 67.9% of adults aged 18–69 are living with overweight or obesity.1,2,3
Diabetes makes the weight-management need more urgent. Across the six GCC markets, IDF country estimates indicate that adults living with diabetes stood at ~8.5 Mn in 2024 and could rise to ~14.5 Mn by 2050. Saudi Arabia alone had ~5.3 Mn adults with diabetes in 2024, projected to reach ~9.5 Mn by 2050, while Kuwait, Qatar and Bahrain are among the highest-prevalence diabetes markets globally.4 Together, these indicators show that weight management in the GCC is becoming a mainstream health need, not only a lifestyle preference. The demand base is not limited to fitness enthusiasts; it includes a much wider population managing excess weight, diabetes risk, cardiovascular risk and long-term health concerns.
Weight loss is becoming a managed consumer-health journey
The second force behind the boom is the way weight loss is expanding from one-off interventions into a more managed journey. The GCC weight-loss market is estimated at ~USD 5.7 Bn in 2025 2024 and growing at a CAGR of ~7.6% CAGR. This is not a narrow gym- or diet-led market. It already includes diet products, fitness equipment, fitness centers, consulting services, surgical clinics and online weight-loss programs.5 This reflects a broader shift in how consumers approach weight management. Instead of relying on a single solution, consumers are increasingly engaging with a mix of products and services across the journey -from diet and fitness to supplements, meal planning, activity tracking, online coaching, teleconsultation, diagnostics, body-composition monitoring and clinical advice.
Related categories are also scaling rapidly. The GCC dietary supplements market is at ~USD 1.72 Bn in 2024 and growing at a CAGR of ~10.8%. Furthermore, the GCC e-health market is at ~USD 3.1 Bn in 2025 and growing at a CAGR of ~14.9%.6,7 Taken together, these trends show that weight loss in the GCC is becoming less of a standalone product category and more of an integrated consumer-health pathway -bringing together nutrition, activity, monitoring, coaching, digital follow-up and clinical support.
Medical weight loss is adding a new clinical layer
GLP-1 drugs are changing the weight-loss conversation because they shift part of the category from effort-led lifestyle change to clinically enabled intervention. The GCC GLP-1 weight-loss drugs market is valued at ~USD 1.1 Bn, driven by rising obesity, diabetes, patient awareness and the introduction of injectable and oral therapies.8 This shift is already visible in the region. The UAE has seen the launch of the pill version of Wegovy, signalling that newer obesity-care formats are entering GCC markets.
At the same time, Saudi Arabia’s SFDA has issued safety communication on GLP-1 receptor agonists and the risk of acute pancreatitis, reinforcing that this category requires clinical supervision, appropriate prescribing and patient education.9,10 The next phase of the GCC weight-loss market will therefore not only be about adoption. It will also require stronger answers around eligibility, side effects, misuse, affordability, insurance coverage, inappropriate use, lifestyle integration and long-term weight maintenance.
